| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 08/04/2021 | 2633.81% | Roth Capital | $45 → $38 | Maintains | Neutral |
| 08/03/2021 | 2633.81% | SVB Leerink | $19 → $38 | Maintains | Market Perform |
| 08/03/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 07/26/2021 | 3137.41% | Roth Capital | $28 → $45 | Maintains | Buy |
| 05/10/2021 | 1266.91% | SVB Leerink | $18 → $19 | Maintains | Market Perform |
| 03/23/2021 | 1194.96% | SVB Leerink | $21 → $18 | Downgrades | Outperform → Market Perform |
| 03/18/2021 | 1914.39% | Roth Capital | $37 → $28 | Maintains | Buy |
| 03/18/2021 | 1914.39% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 03/18/2021 | 1410.79% | SVB Leerink | $33 → $21 | Maintains | Outperform |
| 03/18/2021 | 1410.79% | Evercore ISI Group | → $21 | Downgrades | Outperform → In-Line |
| 03/18/2021 | 1338.85% | Truist Securities | → $20 | Downgrades | Buy → Hold |
| 03/01/2021 | 2274.1% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 11/09/2020 | 2346.04% | SVB Leerink | $30 → $34 | Reiterates | → Outperform |
| 10/05/2020 | 1266.91% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
| 08/19/2020 | 2346.04% | Citigroup | $35 → $34 | Maintains | Buy |
| 07/07/2020 | 2202.16% | HC Wainwright & Co. | $18 → $32 | Maintains | Buy |
| 07/06/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 06/26/2020 | 2058.27% | SVB Leerink | $21 → $30 | Maintains | Outperform |
| 06/26/2020 | 2777.7% | SunTrust Robinson Humphrey | → $40 | Initiates Coverage On | → Buy |
| 07/22/2019 | 1338.85% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 06/18/2019 | 1698.56% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 12/24/2018 | 1410.79% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 11/14/2018 | 1698.56% | Leerink Swann | $24 → $25 | Maintains | Outperform |
What is the target price for Telesis Bio (TBIO)?
The latest price target for Telesis Bio (NASDAQ: TBIO) was reported by Keybanc on August 11, 2023. The analyst firm set a price target for $0.00 expecting TBIO to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Telesis Bio (TBIO)?
The latest analyst rating for Telesis Bio (NASDAQ: TBIO) was provided by Keybanc, and Telesis Bio downgraded their sector weight rating.
When is the next analyst rating going to be posted or updated for Telesis Bio (TBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telesis Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telesis Bio was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Telesis Bio (TBIO) correct?
While ratings are subjective and will change, the latest Telesis Bio (TBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Telesis Bio (TBIO) is trading at is $1.39, which is out of the analyst's predicted range.